Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • china-joins-two-wipo-treaties
    China,  Treaty,  WIPO

    China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

    February 11, 2022

    It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger. We wanted to highlight a few new developments in China. China has joined the Hague System for the International Registration of Industrial Designs, submitting its instrument of accession to the 1999 Geneva Act of the Hague Agreement on February 5, 2022. The Act will go into effect in China on May 5, 2022. The Hague System provides a way for designers to file a single international design application to register up to 100 designs in up to 94 countries.…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • China,  Divisional Applications,  Inventions,  prosecution

    CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

    December 6, 2021

    In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even written about this China divisional patent strategy. However, a recent judgment decision has called this strategy into question. We share more about this interesting case below. Case Background A company in Zhejiang Province (JC Company) filed a divisional application with claims having a different scope of protection from its utility model “parent” (which was about…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • Biotech,  China,  Inventions,  Pharma,  prosecution

    CHINA: How Prohibiting “Illegal” Inventions Runs into Food Safety Law

    October 22, 2021

    Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its face, this provision seems extremely broad, undefined, and potentially very subjective. Whose moral standard? And how do you define “detrimental”? Because details of litigations are not always publicly available in China, we only have limited examples by which we can understand how Chinese courts and examiners interpret and apply this language. Below we highlight one…

    Read More
    eagleip No Comments

    Related Posts

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018

    No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

    November 23, 2018

    Diagnostic Claims in China

    January 9, 2020
 Older Posts
Newer Posts 

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
  • Jan 07, 2026 Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data
  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China

Categories

Archives

  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
  • Jan 07, 2026 Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data
  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China
  • Oct 21, 2025 From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
  • Sep 30, 2025 When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents
  • Sep 18, 2025 Obviousness: can features from different categories of products be combined to invalidate a design patent?
  • Sep 04, 2025 NMPA’s Releases Draft Measures for Data Protection (Data Exclusivity)
  • Jun 03, 2025 How to Protect a Crystal Form (Polymorph) Patent in China
© 2026 Eagle IP Limited
Savona Theme by Optima Themes